"Stabilized Receptor Polypeptides And Uses Thereof" in Patent Application Approval Process (USPTO 20230295267).
In: Gene Therapy Weekly, 2023-10-09, S. 3371-3371
serialPeriodical
Zugriff:
Keywords: Activins; Amgen Inc.; Amino Acids; Biopharmaceutical Companies; Biotechnology; Biotechnology Companies; Business; Drugs and Therapies; Glycoproteins; Gonadal Hormones; Growth Differentiation Factors; Health and Medicine; Healthcare Biotechnology Companies; Intercellular Signaling Peptides and Proteins; Myostatin; Peptide Hormones; Peptide Proteins; Peptides; Peptides and Proteins; Protein Expression; Proteins; Proteomics; TGF-beta Superfamily Proteins; Therapeutics; Therapy; Transforming Growth Factors EN Activins Amgen Inc. Amino Acids Biopharmaceutical Companies Biotechnology Biotechnology Companies Business Drugs and Therapies Glycoproteins Gonadal Hormones Growth Differentiation Factors Health and Medicine Healthcare Biotechnology Companies Intercellular Signaling Peptides and Proteins Myostatin Peptide Hormones Peptide Proteins Peptides Peptides and Proteins Protein Expression Proteins Proteomics TGF-beta Superfamily Proteins Therapeutics Therapy Transforming Growth Factors 3371 3371 1 10/09/23 20231009 NES 231009 2023 OCT 13 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A patent application by the inventors BOONE, Thomas Charles (Newbury Park, CA, US); DESHPANDE, Rohini R. (Camarillo, CA, US); HAN, Huiquan (Thousand Oaks, CA, US); LI, Yue-Sheng (Cambridge, MA, US); MICHAELS, Mark Leo (Encino, CA, US); SUN, Jeonghoon (Poway, CA, US); TAM, Lei-Ting Tony (Thousand Oaks, CA, US), filed on June 7, 2023, was made available online on September 21, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. In another embodiment, the protein comprises a polypeptide having at least 95% sequence identity to SEQ ID NO: 8, 10, 16, or 18, wherein the polypeptide has a W or Y at position 28 and a T at position 44, and wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11. [Extracted from the article]
Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Stabilized Receptor Polypeptides And Uses Thereof" in Patent Application Approval Process (USPTO 20230295267).
|
---|---|
Zeitschrift: | Gene Therapy Weekly, 2023-10-09, S. 3371-3371 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1078-2842 (print) |
Schlagwort: |
|
Sonstiges: |
|